Trial Profile
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Lurbinectedin (Primary)
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Mesothelioma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 26 Nov 2021 Planned number of patients changed from 150 to 320.
- 04 Oct 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2023.
- 04 Oct 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2023.